DE69619753D1 - Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung - Google Patents

Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung

Info

Publication number
DE69619753D1
DE69619753D1 DE69619753T DE69619753T DE69619753D1 DE 69619753 D1 DE69619753 D1 DE 69619753D1 DE 69619753 T DE69619753 T DE 69619753T DE 69619753 T DE69619753 T DE 69619753T DE 69619753 D1 DE69619753 D1 DE 69619753D1
Authority
DE
Germany
Prior art keywords
dpro
arg
inflammation
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619753T
Other languages
English (en)
Other versions
DE69619753T2 (de
Inventor
Yann Mahe
Bruno Buan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of DE69619753D1 publication Critical patent/DE69619753D1/de
Publication of DE69619753T2 publication Critical patent/DE69619753T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
DE69619753T 1995-09-19 1996-08-13 Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung Expired - Lifetime DE69619753T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9510977A FR2738746B1 (fr) 1995-09-19 1995-09-19 Utilisation d'au moins un peptide dans une composition cosmetique ou pour la preparation d'un medicament

Publications (2)

Publication Number Publication Date
DE69619753D1 true DE69619753D1 (de) 2002-04-18
DE69619753T2 DE69619753T2 (de) 2002-08-08

Family

ID=9482701

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619753T Expired - Lifetime DE69619753T2 (de) 1995-09-19 1996-08-13 Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung

Country Status (12)

Country Link
US (2) US20050026845A1 (de)
EP (1) EP0764444B1 (de)
JP (1) JP2831979B2 (de)
AR (1) AR003589A1 (de)
CA (1) CA2185932C (de)
DE (1) DE69619753T2 (de)
ES (1) ES2174039T3 (de)
FR (1) FR2738746B1 (de)
MX (1) MX9710252A (de)
PL (1) PL186767B1 (de)
RU (1) RU2180590C2 (de)
WO (1) WO1997010838A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques
US6803044B1 (en) 1999-03-24 2004-10-12 Zengen, Inc. Antimicrobial and anti-inflammatory peptides for use in human immunodeficiency virus
US6800291B1 (en) 1999-03-24 2004-10-05 Zengen, Inc. Uro-genital condition treatment system
US7402559B2 (en) 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
DE69936142T2 (de) * 1999-10-04 2008-01-24 L'oreal Verwendung eines Hautüberempfindlichkeit vermeidenden Peptids, insbesondere bei kosmetischen Zusammensetzungen
US6780838B2 (en) 2001-01-29 2004-08-24 Zengen, Inc. Compounds for treating fungal pathologies of the oral cavity
US6894028B2 (en) 2001-04-06 2005-05-17 Zengen, Inc. Use of KPV tripeptide for dermatological disorders
FR2826263B1 (fr) 2001-06-26 2005-02-25 Oreal Composition cosmetique ou dermatologique comprenant une association entre un compose inhibiteur de l'elastase de la famille des n-acylaminoamides et au moins un compose anti-inflammatoire
FR2826581B1 (fr) * 2001-06-29 2005-10-07 Oreal Utilisation du tripeptide lys-pro-val (kpv) dans le traitement des melanomes
FR2826580B1 (fr) * 2001-06-29 2005-09-30 Oreal Utilisation du tripeptide lys-pro-val (kpv) pour favoriser le renouvellement epidermique et la micro-cicatrisation cutanee superficielle et/ou ameliorer l'aspect esthetique des plaies et cicatrices
FR2827170B1 (fr) 2001-07-13 2004-07-16 Soc Extraction Principes Actif Utilisation de peptides pour augmenter l'adhesion cellulaire
US7115574B2 (en) 2001-12-10 2006-10-03 Zengen, Inc. System and method for support legacy operating system booting in a legacy-free system
US6939846B2 (en) 2001-12-17 2005-09-06 Zengen, Inc. Use of a polypeptide for treatment of pruritis in animals
AU2003292326A1 (en) * 2002-11-08 2004-06-03 Societe D'extraction Des Principes Actifs (Vincience) Cosmetic or pharmaceutical composition comprising peptides with the sequence arg-gly-ser
FR2846883B1 (fr) * 2002-11-08 2004-12-24 Vincience Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
US9387235B2 (en) 2004-06-14 2016-07-12 Basf Beauty Care Solutions France S.A.S. Cosmetic preparations containing PTH fragments
US7300649B2 (en) 2005-02-11 2007-11-27 Genepharm, Inc. Cosmetic and cosmeceutical compositions for restoration of skin barrier function
WO2011069643A2 (en) * 2009-12-08 2011-06-16 Amsilk Gmbh Silk protein coatings
JP6893086B2 (ja) 2013-03-13 2021-06-23 エーブリー デニソン コーポレイション 接着特性の向上
MX368628B (es) * 2013-09-23 2019-10-08 Dr August Wolff Gmbh & Co Kg Arzneimittel Tripeptidos antiinflamatorios.
KR102208853B1 (ko) * 2018-05-08 2021-01-28 오션펩 주식회사 주름개선 효능을 갖는 펩티드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157023A (en) * 1984-08-21 1992-10-20 Lipton James M Antipyretic and anti-inflammatory lys pro val compositions and method of use
US5028592A (en) * 1986-08-08 1991-07-02 Lipton James M Antipyretic and anti-inflammatory peptides
US4878744A (en) * 1985-12-30 1989-11-07 Capitol Records, Inc. Three dimensional reflex lens systems
AU604751B2 (en) * 1986-08-08 1991-01-03 Board Of Regents, The University Of Texas System Anti-inflammatory peptides
EP0335662B1 (de) * 1988-03-28 1995-07-26 Btg International Limited Peptide
GB8807427D0 (en) * 1988-03-28 1988-05-05 National Biological Standards Board Peptides
FR2784028B1 (fr) * 1998-10-01 2003-02-07 Oreal Utilisation d'un peptide prevenant les reactions d'intolerance de la peau, notamment dans des compositions cosmetiques

Also Published As

Publication number Publication date
JP2831979B2 (ja) 1998-12-02
CA2185932A1 (fr) 1997-03-20
JPH09124502A (ja) 1997-05-13
EP0764444B1 (de) 2002-03-13
AR003589A1 (es) 1998-08-05
US20080038208A1 (en) 2008-02-14
PL324485A1 (en) 1998-05-25
WO1997010838A1 (fr) 1997-03-27
DE69619753T2 (de) 2002-08-08
RU2180590C2 (ru) 2002-03-20
MX9710252A (es) 1998-03-31
CA2185932C (fr) 2003-11-11
PL186767B1 (pl) 2004-02-27
EP0764444A1 (de) 1997-03-26
FR2738746A1 (fr) 1997-03-21
ES2174039T3 (es) 2002-11-01
US20050026845A1 (en) 2005-02-03
FR2738746B1 (fr) 1997-11-14

Similar Documents

Publication Publication Date Title
DE69619753T2 (de) Verwendung mindestens eines die Tripeptidsequenz Lys-DPro-Arg enthaltenden Peptids zur Herstellung eines Arzneimittels zur Behandlung einer Entzündung
DE69435116D1 (de) Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
BR9606607A (pt) Composto método de aperfeiçoamento de transporte de uma droga ou outro ativo método de fabricação de um medicamento composto uso método de tratamento de uma doença e método de preparação de um medicamento
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DE59608738D1 (de) Verwendung von epinastin für die behandlung von schmerzen
DE69331207D1 (de) Verfahren zur Behandlung eines resorbierbaren Implantationsmaterials
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE69934813D1 (de) Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
DE69010251D1 (de) Dentale Einheit zur Behandlung eines Wurzelkanals.
DE69925488D1 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
DE69600983D1 (de) Kapselpräparate zur Behandlung von Pflanzen
DE69417115T2 (de) Verfahren zur Herstellung chirurgischen Nahtmaterials
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
ATE221763T1 (de) Die verwendung von glyceryltriacetat zur behandlung von onychomykosen
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
FR2735133B1 (fr) Procede de preparation d'un analogue de polypeptide a electro-transportabilite amelioree a travers la peau et son utilisation
DE69534325D1 (de) Peptide zur behandlung von krebs
DE59810043D1 (de) Verfahren zur Herstellung eines pharmazeutisch aktiven Peptides
DE69614739T2 (de) Pflaster zur Behandlung von Pflanzen
DE69632677D1 (de) Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
ATE190494T1 (de) Verwendung von gnrh-antagonisten zur herstellung eines medikaments zur behandlung gonaden-steroid abhängiger erkrankungen
NO973366D0 (no) Fremgangsmåte for behandling av multippel sklerose
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition